TGFB2 and cancer: We additionally employed the Kaplan‐Meier plotter database in order to assess how TGFβ2 expression relates to prognosis in a range of cancer types, revealing its elevation to be significantly linked with a poorer prognosis in gastric cancer (OS HR = 1.62, 95% CI = 1.35–1.98, P = 1.97e‐7; PFS HR = 1.82, 95% CI = 1.48–2.24, P = 7.6e‐9) and ovarian cancer (OS HR = 1.18, 95% CI = 1.04 to 1.34, P = .013; PFS HR = 1.35, 95% CI = 1.18–1.55, P = 1.4e‐5) (Figure 2I–L).